NFKB1 and Insulin resistance: We found that treatment with the Ras inhibitor, F-FTS, reduced insulin-resistance in vitro and attenuated type 2 diabetes in vivo. The effects of Ras inhibition were mediated by the IKB/NF-κB cascade.